M&A and investment
Linden Therapeutics, a US specialty pharmaceutical company facing a patent cliff, must decide which of three rare-disease assets to acquire from a set of three targets, at what price, and how to finance the transactions under binding debt covenants.
← Back to the case library · How M&A cases run
Linden Therapeutics is a US publicly traded specialty pharmaceutical company headquartered in Boston, Massachusetts, focused on neurology. In FY2024 it generated revenue of $680.0M, EBITDA of $198.0M, and employs a field commercial organization of roughly 80 specialty sales representatives calling on about 1,200 neuromuscular and movement-disorder specialists nationwide. Its flagship product, Reltora (for a chronic adult neuropathy), accounts for 62% of revenue and loses market exclusivity in three years, when a generic will erode an estimated 40-50% of that product's sales within two years. The board has approved a strategy of building a "rare neuromuscular franchise" through acquisition to offset this cliff.
Management has shortlisted three privately held targets, all selling into the same 1,200-specialist physician base:
- **Aurora Neuroscience** (Aurora): developer of Aurora-1, an antisense oligonucleotide for SPN1 deficiency, an ultra-rare pediatric neuromuscular disease with roughly 780 diagnosed patients in the US. Aurora has 520 patients on therapy and generated $103.9M of revenue in FY2024 with $36.0M of EBITDA. Asking price: $410M. Its growth plan assumes a 9% revenue CAGR driven by newborn-screening expansion, a European launch, and annual price steps. - **Brookside Biologics** (Brookside): manufacturer of Brookzyme, an enzyme-replacement therapy for a lysosomal storage disorder with roughly 2,000 treated patients globally. FY2024 revenue of $310.0M, EBITDA of $96.1M, growing about 4% per year. The seller is running a two-bidder process and is asking $750M, a price management believes already reflects the competing bidder's valuation of Brookside's early-stage gene-therapy pipeline. - **Crestline Therapeutics** (Crestline): a developer of a wearable neuromodulation device with a remote therapeutic monitoring software subscription, prescribed for neuromuscular patients by the same specialists. FY2024 revenue of $54.0M growing 32% per year, EBITDA of $9.0M. Asking price: $180M.
The two mid-size assets (Aurora and Brookside) are expensive but cash-generative; the small one (Crestline) is dilutive at the EBITDA line but growing quickly and dense with synergy potential. Linden's CFO has flagged that the CEO's instinct to buy all three at once would require more leverage and new equity than the board allows, and the chief medical officer questions whether Brookside's lysosomal disease fits the neuromuscular franchise strategy at all.
One thing stands out in Aurora's deal book: a 2025 plan that embeds another 9% revenue step even though its treated-patient counts in the vendor due-diligence appendix are essentially flat, and roughly 70% of its revenue now flows from a single state's catastrophic-disease drug program that is being audited by the state legislature. Nobody at Linden has yet reconciled the price story with the volume story. The key decision is which targets to acquire, at what price, how to finance the combination within the board's covenants, and how to sequence and integrate the chosen deals.
Structuring Judgement Numeracy Creativity SynthesisCase Ace opens the case, poses the questions one at a time, reveals exhibits at the right moments and scores you against the model answer. Included in the MBB bundle — £40 for everything.
or get access to everything →